Inventor · disambiguated record
Anthony C. Blackburn
Also filed as: BLACKBURN ANTHONY C · BLACKBURN ANTHONY CLYDE
26 granted patents·14 pending applications·281 citations·filing 2004–2025
96Inventor score
Top patents by PatentIndex Score
40 records- 0197US11091435B2Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P1 receptor-associated disordersARENA PHARM INC·Filed 2020·Granted Aug 17, 2021·11 cites·15 claims
- 0297US10676435B2Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disordersARENA PHARM INC·Filed 2019·Granted Jun 9, 2020·12 cites·25 claims
- 0396US11884626B2Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disordersARENA PHARM INC·Filed 2021·Granted Jan 30, 2024·3 cites·16 claims
- 0496US11771695B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2021·Granted Oct 3, 2023·4 cites·11 claims
- 0595US10479797B2Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoARENA PHARM INC·Filed 2019·Granted Nov 19, 2019·9 cites·30 claims
- 0694US11560369B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsARENA PHARM INC·Filed 2021·Granted Jan 24, 2023·2 cites·20 claims
- 0794US7863278B2Isethionate salt of a selective CDK4 inhibitorWARNER LAMBERT COMPANYLLC·Filed 2007·Granted Jan 4, 2011·54 cites·4 claims
- 0894US7345171B2Isethionate salt of a selective CKD4 inhibitorWARNER LAMBERT CO·Filed 2004·Granted Mar 18, 2008·103 cites·10 claims
- 0993US10981895B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsARENA PHARM INC·Filed 2018·Granted Apr 20, 2021·4 cites·16 claims
- 1093US10301262B2Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disordersARENA PHARM INC·Filed 2016·Granted May 28, 2019·11 cites·50 claims
- 1193US10183930B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsARENA PHARM INC·Filed 2016·Granted Jan 22, 2019·10 cites·11 claims
- 1293US9458136B2Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsBLACKBURN ANTHONY C·Filed 2012·Granted Oct 4, 2016·11 cites·34 claims
- 1392US10632134B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2017·Granted Apr 28, 2020·5 cites·16 claims
- 1491US10927123B2Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoARENA PHARM INC·Filed 2020·Granted Feb 23, 2021·2 cites·6 claims
- 1591US10662200B2Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoARENA PHARM INC·Filed 2019·Granted May 26, 2020·3 cites·24 claims
- 1691US9867822B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2016·Granted Jan 16, 2018·7 cites·18 claims
- 1791US9492447B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2015·Granted Nov 15, 2016·9 cites·20 claims
- 1890US12378198B2Crystalline l-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in SIPI receptor-associated disordersARENA PHARM INC·Filed 2023·Granted Aug 5, 2025·0 cites·40 claims
- 1989US2025346560A1Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disordersARENA PHARM INC·Filed 2025·Application pending·0 cites
- 2088US9597340B2Cannabinoid receptor modulatorsTHATTE JAYANT·Filed 2012·Granted Mar 21, 2017·9 cites·17 claims
- 2186US11560386B2Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoARENA PHARM INC·Filed 2020·Granted Jan 24, 2023·1 cites·19 claims
- 2280US9045431B2Processes for the preparation of 5-HT2C receptor agonistsBLACKBURN ANTHONY C·Filed 2011·Granted Jun 2, 2015·3 cites·28 claims
- 2377US9365521B2Non-hygroscopic salts of 5-HT2C agonistsBLACKBURN ANTHONY C·Filed 2011·Granted Jun 14, 2016·4 cites·26 claims
- 2475US9248133B2Salts of lorcaserin with optically active acidsBLACKBURN ANTHONY C·Filed 2011·Granted Feb 2, 2016·3 cites·24 claims
- 2572US10226471B2Modified-release dosage forms of 5-HT2C agonists useful for weight managementARENA PHARM INC·Filed 2017·Granted Mar 12, 2019·1 cites·7 claims
- 2667US2020069681A1Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2019·Application pending·0 cites
- 2766US2019284200A1Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoARENA PHARM INC·Filed 2017·Application pending·0 cites
- 2864US12109219B2Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2020·Granted Oct 8, 2024·0 cites·20 claims
- 2964US2024409548A1Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related theretoARENA PHARM INC·Filed 2022·Application pending·0 cites
- 3063US2018280386A1Cannabinoid receptor modulatorsARENA PHARM INC·Filed 2017·Application pending·0 cites
- 3159US10463676B2Modified-release dosage forms of 5-HT2C agonists useful for weight managementARENA PHARM INC·Filed 2019·Granted Nov 5, 2019·0 cites·15 claims
- 3256US2025034090A1Novel s1p1 receptor agonist, crystalline salts, processes for preparing, and uses related theretoARENA PHARM INC·Filed 2023·Application pending·0 cites
- 3355US2014206649A1Cannabinoid receptor modulatorsTHATTE JAYANT·Filed 2012·Application pending·0 cites
- 3447US2013315994A1Modified-release dosage forms of 5-ht2c agonists useful for weight managementSHAO ZEZHI JESSE·Filed 2011·Application pending·0 cites
- 3547US2010292288A1Crystalline forms of (r)-1-{2-[4`- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related theretoARENA PHARM INC·Filed 2008·Application pending·0 cites
- 3643US2017096398A1Non-hygroscopic salts of 5-ht2c agonistsARENA PHARM INC·Filed 2016·Application pending·0 cites
- 3741US2016151381A1Salts of lorcaserin with optically active acidsARENA PHARM INC·Filed 2015·Application pending·0 cites
- 3840US2014309192A1Modulators of the g protein-coupled mas receptor and the treatment of disorders related theretoARENA PHARM INC·Filed 2012·Application pending·0 cites
- 3938US2014148442A1Fast-dissolve dosage forms of 5-ht2c agonistsBLACKBURN ANTHONY C·Filed 2011·Application pending·0 cites
- 4034US2012225937A1Crystalline forms and processes for the preparation of pg12 receptor agonistsBLACKBURN ANTHONY C·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Anthony C. Blackburn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →